285 related articles for article (PubMed ID: 29714570)
1. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
[TBL] [Abstract][Full Text] [Related]
2. Off-Label Prescribing of Psychotropic Medication, 2005-2013: An Examination of Potential Influences.
O'Brien PL; Cummings N; Mark TL
Psychiatr Serv; 2017 Jun; 68(6):549-558. PubMed ID: 28093058
[TBL] [Abstract][Full Text] [Related]
3. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
[TBL] [Abstract][Full Text] [Related]
4. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
[No Abstract] [Full Text] [Related]
5. Age-related off-label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan.
Park B; Lee H; Choi H; Lee J
Clin Transl Sci; 2024 Jul; 17(7):e13869. PubMed ID: 38946123
[TBL] [Abstract][Full Text] [Related]
6. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
Schwartz LM; Woloshin S; Lu Z; Ross KM; Tessema FA; Peter D; Kesselheim AS
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006073. PubMed ID: 31707825
[TBL] [Abstract][Full Text] [Related]
7. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
8. Overview of FDA Drug Approval and Labeling.
Clarridge KE; Chin SJ; Stone KD
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3051-3056. PubMed ID: 36496207
[TBL] [Abstract][Full Text] [Related]
9. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
[TBL] [Abstract][Full Text] [Related]
10. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
11. Association between the commercial characteristics of psychotropic drugs and their off-label use.
Graziul C; Gibbons R; Alexander GC
Med Care; 2012 Nov; 50(11):940-7. PubMed ID: 23047783
[TBL] [Abstract][Full Text] [Related]
12. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
Baker R
BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
[TBL] [Abstract][Full Text] [Related]
13. Off-label drug use in children should be rational.
Bonati M; Pandolfini C
Arch Dis Child; 2011 Sep; 96(9):870-1. PubMed ID: 21715392
[No Abstract] [Full Text] [Related]
14. Introduction: on-label and off-label drug use in reproductive medicine.
Legro RS
Fertil Steril; 2015 Mar; 103(3):581-2. PubMed ID: 25726701
[TBL] [Abstract][Full Text] [Related]
15. Primary care physicians' use of FDA-approved prescription drug labels.
Sullivan HW; O'Donoghue AC; Aikin KJ
J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
[TBL] [Abstract][Full Text] [Related]
16. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores.
Carvalho CG; Ribeiro MR; Bonilha MM; Fernandes M; Procianoy RS; Silveira RC
J Pediatr (Rio J); 2012; 88(6):465-70. PubMed ID: 23108602
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Clinical Compendia Used for Medicare Part D Coverage Determinations for Off-label Prescribing in Dermatology.
Barbieri JS; St Claire K; Mostaghimi A; Albrecht J
JAMA Dermatol; 2019 Mar; 155(3):315-320. PubMed ID: 30673082
[TBL] [Abstract][Full Text] [Related]
18. Introduction to the new prescription drug labeling by the Food and Drug Administration.
Lal R; Kremzner M
Am J Health Syst Pharm; 2007 Dec; 64(23):2488-94. PubMed ID: 18029957
[TBL] [Abstract][Full Text] [Related]
19. Off-label drug use in human immunodeficiency virus disease.
Brosgart CL; Mitchell T; Charlebois E; Coleman R; Mehalko S; Young J; Abrams DI
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):56-62. PubMed ID: 8624761
[TBL] [Abstract][Full Text] [Related]
20. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
